KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Accumulated Depreciation & Amortization (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $10.0 million as the latest value for Q1 2023.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 21.98% to $10.0 million in Q1 2023 year-over-year; TTM through Mar 2023 was $10.0 million, a 21.98% increase, with the full-year FY2022 number at $9.6 million, up 25.01% from a year prior.
  • Accumulated Depreciation & Amortization was $10.0 million for Q1 2023 at Palvella Therapeutics, up from $9.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $10.0 million in Q1 2023 to a low of $3.3 million in Q1 2019.
  • A 5-year average of $5.8 million and a median of $5.4 million in 2020 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: increased 2.73% in 2019, then skyrocketed 68.16% in 2021.
  • Palvella Therapeutics' Accumulated Depreciation & Amortization stood at $3.6 million in 2019, then surged by 63.02% to $5.8 million in 2020, then surged by 32.71% to $7.7 million in 2021, then rose by 25.01% to $9.6 million in 2022, then increased by 3.39% to $10.0 million in 2023.
  • Per Business Quant, the three most recent readings for PVLA's Accumulated Depreciation & Amortization are $10.0 million (Q1 2023), $9.6 million (Q4 2022), and $8.2 million (Q1 2022).